Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CASP1 | P29466 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320562 | 0.91 | MAPK1 (0.65) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL31237204 | 0.91 | MAPK1 (0.65) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL5959439 | 0.88 | MEN1 (0.67) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL4327635 | 0.87 | ALDH1A1 (0.62) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL4336221 | 0.86 | KDM4E (0.58) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL5959320 | 0.86 | NPC1 (0.73) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL4334941 | 0.86 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL4326091 | 0.84 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL4426711 | 0.84 | MEN1 (1.00) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL4427840 | 0.84 | MEN1 (0.71) | MEN1KMT2AALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392683-A4 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-10-26 | — | — | EP | claimed |
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-07-14 | — | — | US | claimed |
| EP-1392683-A1 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-03 | — | — | US | claimed |
| WO-2002092594-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| EP-1230232-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001034591-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-05-17 | — | — | WO | claimed |
| US-7507762-B2 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7053117-B2 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| EP-1392683-A4 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-07-14 | — | — | US | disclosed |
| US-6906203-B1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1392683-A1 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002092594-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| EP-1230232-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034591-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, CASP5 | MEN1 2868/4885KMT2A 3138/4885ALDH1A1 2306/4885 |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP4, CASP3, CASP7 | MEN1 2444/4885KMT2A 2978/4885ALDH1A1 2014/4885 |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP5, CASP1 | MEN1 2109/4885KMT2A 3266/4885ALDH1A1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.